| Antitumor effects of recombinant human interferon α-2a and hydroxyurea against chronic myelogenous leukemia |
|
Chang-hwan Kim1, Beom-jun Lee2, Jong-hwan Park1, Jae-hak Park1 |
1Department Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University
2Veterinary Public Health, College of Veterinary Medicine, Seoul National University |
| 만성 골수성 백혈병에 대한 유전자 재조합 인터페론 α-2a와 hydroxyurea의 항암효과 |
|
김창환1, 이범준2, 박종환1, 박재학1 |
1서울대학교 수의과대학 실험동물의학교실
2서울대학교 수의과대학 수의공중보건학교실 |
|
|
| Abstract |
|
Prior to a clinical trial, the in vitro and in vivo antitumor effects of a new recombinant human interferon ${alpha}-2a$ (rHu/IFN ${alpha}-2a$) with/without hydroxyurea (HU) were investigated using chronic myelogenous leukemia (CML)-derived cell lines (K562 and KU812F) and BALB/c nude. mice transplanted with KU812F cells. The rHu/IFN ${alpha}-2a$ ($10^4-10^6IU/ml$) strongly inhibited proliferation of both cell lines and the combined treatments with HU ($10{mu}g/ml$) were more effective. In nude mice transplanted with KU812F cells. rHu/IFN ${alpha}-2a(1{ imes}10^6IU$) inhibited tumor growth by 42-65% at 15-21 days post-transplantation (DPT). The combined treatment of rHu/IFN ${alpha}-2a (5{ imes}10^5IU$) with HU (0.25mg/g b.w.) inhibited the tumor growth by 48-67% at 12-21 DPT. In addition, the treatment of rHu/IFN ${alpha}-2a$ ($5{ imes}10^6IU;or;1{ imes}10^7IU$) rejected tumor transplantation by 40%. These results suggest that the new rHU/IFN ${alpha}-2a$ alone or with HU is effective on CML cell lines. |
| Key Words:
chronic myelogenous leukemia (CML), hydroxyurea, interferon c-2a, K562, Ku812F, nude mice |
|
PDF Links
Full text via DOI
Download Citation
